John Leidy
Endocrinology, Diabetes & Metabolism · Huntington, WVNPI 1528174059
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 12 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 8 manufacturers reported payments, led by Novo Nordisk at 28.9% of the total. Reporting peaked in 2024 at $553 and has fallen 77.5% since, to $124 in 2025. That places this record below the midpoint for endocrinology, diabetes & metabolism clinicians in WV, where the typical reported total is $1,166.
Across 12 payments — averaging $72.00 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$249
- Abbott$158
- Xeris Pharmaceuticals, Inc.$127
- Sanofi-aventis U.S. LLC$122
- Dexcom, Inc.$95
- Tandem Diabetes Care, Inc.$66
- plus $46 from 2 others
What the payments were for
- Food & beverage$864100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 2 | $249 |
| Abbott | 4 | $158 |
| Xeris Pharmaceuticals, Inc. | 1 | $127 |
| Sanofi-aventis U.S. LLC | 1 | $122 |
| Dexcom, Inc. | 1 | $95 |
| Tandem Diabetes Care, Inc. | 1 | $66 |
| Medtronic | 1 | $24 |
| Insulet Corporation | 1 | $22 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Wegovy$249
- GVOKE HYPOPEN$127
- TZIELD$122
- FREESTYLE LIBRE 3$117
How this compares
$864 in reported general payments places this provider in the 40th percentile of 57 endocrinology, diabetes & metabolism providers in West Virginia.
See all endocrinology, diabetes & metabolism providers in West Virginia →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 11 | $17,773 |
| Atorvastatin Calcium | 11 | $206 |
| Levothyroxine Sodium | 16 | $176 |
Paid to pharmacies, not to this prescriber.
Other endocrinology, diabetes & metabolism in Huntington
- Daniel MaciasHuntington$686K
- Ayman ElkadryHuntington$13K
- Henry DriscollHuntington$1K
- Mateen HotianaHuntington$1K
- Ronald InnerfieldHuntington$833
- Sobia FaisalHuntington$705
- Henin AlsamarraieHuntington$695
- Nesreen BenhamedHuntington$526
- Maria Luzuriaga BassanteHuntington$421
- Muhammad HaqHuntington$280
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.